8-K: FOXO Technologies to Acquire Vector Biosource Inc. in Non-Binding Agreement

FOXO Technologies Inc. announces a non-binding agreement to acquire Vector Biosource Inc., a biospecimen sourcing provider, for a combination of preferred stock and earnout payments.

Summary

• FOXO Technologies Inc. has signed a non-binding agreement to acquire Vector Biosource Inc.
• Vector Biosource is a provider of information and biospecimens to the biotechnology, clinical research, and pharmaceutical research industries.
• Vector is expected to generate $800,000 in revenues in 2025 without additional capital.
• The purchase price includes $750,000 in Series D Preferred Stock, an additional $750,000 in Series D Preferred Stock upon achieving certain milestones in 2025, and earnout payments in Series D Preferred Stock based on revenues and cash collections in 2026 and 2027.
• The closing of the transaction is subject to definitive agreements within 45 days, satisfactory due diligence, provision of $1 million of working capital, and other closing conditions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition could be beneficial, but it's a non-binding agreement with risks and uncertainties. The use of preferred stock could dilute existing shareholders.

Positives

• The acquisition of Vector Biosource could provide FOXO with a unique position in the healthcare sector.
• Vector's expected revenue of $800,000 in 2025 could contribute to FOXO's overall revenue.
• The acquisition may allow Vector to achieve its near and long-term growth plans by providing growth capital, corporate infrastructure, and potential synergies with other FOXO subsidiaries.
• Vector anticipates a significant increase in expected revenues with the provision of growth capital and corporate infrastructure by FOXO.

Negatives

• The agreement is non-binding, meaning the acquisition may not be completed.
• The closing is subject to several conditions, including satisfactory due diligence and the provision of $1 million in working capital, which could pose challenges.
• The purchase price includes Series D Preferred Stock, which could dilute existing shareholders' equity.
• FOXO has a history of losses and may not achieve or maintain profitability in the future.

Risks

• The acquisition is subject to risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.
• These risks include changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors, and changes in laws and regulations affecting FOXO's business.
• The company's ability to obtain financing and maintain relationships required to advance its goals is also a risk.
• There is a risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates.

Future Outlook

The company anticipates a significant increase in expected revenues with the provision of growth capital and corporate infrastructure by FOXO, and is focused on working closely with Vector senior leadership to aggressively expand the Vector platform.

Management Comments

• Seamus Lagan, CEO of FOXO, stated that they were attracted to Vector's unique position in the healthcare sector and its growth profile.
• Frank Dias, Jr., CEO of Vector, believes the partnership with FOXO will allow Vector to achieve its near and long term growth plans by providing growth capital, corporate infrastructure and potential synergies with other FOXO subsidiaries.

Industry Context

The acquisition of Vector Biosource aligns with the trend of healthcare companies expanding their service offerings through strategic acquisitions to gain access to new markets and technologies.

Comparison to Industry Standards

• It is difficult to compare this specific acquisition to industry standards without knowing the exact multiples being paid for Vector's revenue and potential future earnings.
• Similar acquisitions in the biospecimen sourcing space often involve a multiple of revenue or EBITDA, depending on the profitability and growth prospects of the target company.
• The use of preferred stock as part of the purchase price is not uncommon, especially for smaller acquisitions or companies with limited cash resources.

Stakeholder Impact

• Shareholders may experience dilution if the Series D Preferred Stock is issued.
• Employees of Vector Biosource may benefit from the acquisition through increased growth opportunities.
• Customers of Vector Biosource may benefit from the potential synergies and expanded platform.

Next Steps

• Completion of definitive agreements within 45 days.
• Satisfactory due diligence.
• Provision of $1 million of working capital.
• Closing of the transaction.

Key Dates

Keywords

acquisition, Vector Biosource, FOXO Technologies, biospecimen sourcing, Series D Preferred Stock, non-binding agreement, healthcare, biotechnology